[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"confocal-laser-endomicroscopy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:confocal-laser-endomicroscopy":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100633048","one-stop-diagnosis-and-treatment-for-suspected-lung-cancer-combined-rbs-ncle-obct-and-ablation-100633048",false,"NCT07521618","One-stop Diagnosis and Treatment for Suspected Lung Cancer: Combined RBS, nClE, OBCT and Ablation","An Exploratory Clinical Trial on the Integration of Detection, Sampling and Treatment of Peripheral Lung Cancer by Robotic Bronchoscopy System","One-stop","Inclusion Criteria:\n\n* Age ≥18 years, male or female.\n* High-risk pulmonary nodule\u002Ftumor maximum diameter ≤3 cm.\n* Lesion judged suitable for bronchial navigation-guided diagnosis and treatment.\n* Ineligible for surgery or refuses surgery\u002Fradiotherapy; agrees to primary ablation therapy; provides written informed consent.\n\nExclusion Criteria:\n\n* Diffuse bilateral lung lesions unresponsive to ablation.\n* Contraindication to bronchoscopy or inability to tolerate\u002Fcooperate with bronchoscopy.\n* Severe bleeding tendency or irreversible coagulopathy (PT \\>18 s, PTA \\\u003C40%).Platelet count \\\u003C70×10⁹\u002FL; anticoagulant\u002Fantiplatelet therapy discontinued \\\u003C1 week before ablation (except prophylactic low-molecular-weight heparin).\n* Severe pulmonary impairment (maximal voluntary ventilation \\\u003C40%).\n* Other metastatic tumors with widespread metastasis; life expectancy \\\u003C3 months.\n* Poor general condition: widespread metastasis, severe infection, high fever, infectious\u002Fradiation inflammation around the lesion, obvious cachexia, severe organ dysfunction, severe anemia, uncorrectable metabolic\u002Fnutritional disorders.\n* Eastern Cooperative Oncology Group (ECOG) performance status \\>2.\n* Target lesion received radiotherapy within the past 6 months.\n* Active hepatitis B, active hepatitis C, known HIV-1\u002F2 antibody positivity, or other active infections judged by the investigator to interfere with treatment.\n* History of epilepsy, psychosis, or cognitive impairment.\n* Pregnant\u002Flactating females; males or females planning conception during the trial.\n* Other conditions deemed inappropriate by the investigator.","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","Using RBS as the navigation and treatment platform, precisely navigate to the target lesion. Utilize r-EUBS and nCLE to identify the lesion, and when the confocal AI model recognizes the lesion as malignant, perform a biopsy. Subsequently, under the guidance of OBCT, carry out ablation treatment of the lesion.",[27,28,29,30],"Lung Cancer (Suspected or Confirmed)","Cryoablation","Robotic Bronchoscopy System","Confocal Laser Endomicroscopy","NOT_YET_RECRUITING","2026-04-08",{"date":34,"type":35},"2026-04-13","ACTUAL",{"date":37,"type":21},"2026-04-01",{"date":39,"type":21},"2026-12-31",{"name":41,"class":42},"Guangzhou Medical University","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100589790","confocal-histolog-scanner-in-routine-breast-conserving-surgery-chib-100589790","NCT06958991","Confocal Histolog Scanner in Routine Breast-Conserving Surgery (CHiB)","Confocal Histolog Scanner in Routine Breast-Conserving Surgery","CHiB","Inclusion Criteria:\n\n* Adult female Subject ≥18 years old.\n* Subject scheduled for breast conserving surgery of invasive and\u002For in-situ ductal and lobular carcinoma.\n* Subject is able to read, understand and sign the informed consent.\n\nExclusion Criteria:\n\n* Subject with planned mastectomy\n* Subject does not speak French- Subject with planned tumor-adapted breast reduction\n* Subject is pregnant\u002F lactating. Subjects pregnant\u002Flactating are excluded because such subjects are presenting additional risks during the surgery and they are also rare.\n* Participation in any other clinical study that would affect data acquisition.","FEMALE",{"count":53,"type":21},100,[24],"The clinical performance study is collecting data from the use of a CE mark product used within the scope of its intended purpose to intraoperatively visualize tissue specimen. The subjects are not submitted to invasive and burdensome procedures compared to the standard of care surgical practices and regular use of the CE mark product.",[57,58,59,30],"Breast Cancer Invasive","Breast Cancer Surgery","Lumpectomy",[61,62],"breast cancer surgery","confocal microscopy","RECRUITING","2025-11-22",{"date":66,"type":35},"2025-11-25",{"date":68,"type":35},"2025-06-01",{"date":70,"type":21},"2026-09-30",{"name":72,"class":42},"University of Fribourg",1]